CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
Multiple myeloma (MM) is an incurable malignancy of the B-cell lineage. Remarkable progress has been made in the treatment of MM with anti-CD38 monoclonal antibodies such as daratumumab and isatuximab, which can kill MM cells by inducing complement-dependent cytotoxicity (CDC). We showed that the CD...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Cancer Biology & Therapy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/15384047.2024.2314322 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126032471457792 |
|---|---|
| author | Hongjie Wang Theo Koob Jonathan R. Fromm Ajay Gopal Darrick Carter André Lieber |
| author_facet | Hongjie Wang Theo Koob Jonathan R. Fromm Ajay Gopal Darrick Carter André Lieber |
| author_sort | Hongjie Wang |
| collection | DOAJ |
| description | Multiple myeloma (MM) is an incurable malignancy of the B-cell lineage. Remarkable progress has been made in the treatment of MM with anti-CD38 monoclonal antibodies such as daratumumab and isatuximab, which can kill MM cells by inducing complement-dependent cytotoxicity (CDC). We showed that the CDC efficacy of daratumumab and isatuximab is limited by membrane complement inhibitors, including CD46 and CD59, which are upregulated in MM cells. We recently developed a small recombinant protein, Ad35K++, which is capable of transiently removing CD46 from the cell surface. We also produced a peptide inhibitor of CD59 (rILYd4). In this study, we tested Ad35K++ and rILYd4 in combination with daratumumab and isatuximab in MM cells as well as in cells from two other B-cell malignancies. We showed that Ad35K++ and rILYd4 increased CDC triggered by daratumumab and isatuximab. The combination of both inhibitors had an additive effect in vitro in primary MM cells as well as in vivo in a mouse xenograft model of MM. Daratumumab and isatuximab treatment of MM lines (without Ad35K++ or rILYd4) resulted in the upregulation of CD46/CD59 and/or survival of CD46high/CD59high MM cells that escaped the second round of daratumumab and isatuximab treatment. The escape in the second treatment cycle was prevented by the pretreatment of cells with Ad35K++. Overall, our data demonstrate that Ad35K++ and rILYd4 are efficient co-therapeutics of daratumumab and isatuximab, specifically in multi-cycle treatment regimens, and could be used to improve treatment of multiple myeloma. |
| format | Article |
| id | doaj-art-085b2858ebc84b6db574179c60218a9e |
| institution | Kabale University |
| issn | 1538-4047 1555-8576 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Cancer Biology & Therapy |
| spelling | doaj-art-085b2858ebc84b6db574179c60218a9e2024-12-13T06:53:24ZengTaylor & Francis GroupCancer Biology & Therapy1538-40471555-85762024-12-0125110.1080/15384047.2024.2314322CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cellsHongjie Wang0Theo Koob1Jonathan R. Fromm2Ajay Gopal3Darrick Carter4André Lieber5Department of Medicine, University of Washington, Seattle, WA, USADepartment of Medicine, University of Washington, Seattle, WA, USADepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USADepartment of Medicine, University of Washington, Seattle, WA, USADepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USADepartment of Medicine, University of Washington, Seattle, WA, USAMultiple myeloma (MM) is an incurable malignancy of the B-cell lineage. Remarkable progress has been made in the treatment of MM with anti-CD38 monoclonal antibodies such as daratumumab and isatuximab, which can kill MM cells by inducing complement-dependent cytotoxicity (CDC). We showed that the CDC efficacy of daratumumab and isatuximab is limited by membrane complement inhibitors, including CD46 and CD59, which are upregulated in MM cells. We recently developed a small recombinant protein, Ad35K++, which is capable of transiently removing CD46 from the cell surface. We also produced a peptide inhibitor of CD59 (rILYd4). In this study, we tested Ad35K++ and rILYd4 in combination with daratumumab and isatuximab in MM cells as well as in cells from two other B-cell malignancies. We showed that Ad35K++ and rILYd4 increased CDC triggered by daratumumab and isatuximab. The combination of both inhibitors had an additive effect in vitro in primary MM cells as well as in vivo in a mouse xenograft model of MM. Daratumumab and isatuximab treatment of MM lines (without Ad35K++ or rILYd4) resulted in the upregulation of CD46/CD59 and/or survival of CD46high/CD59high MM cells that escaped the second round of daratumumab and isatuximab treatment. The escape in the second treatment cycle was prevented by the pretreatment of cells with Ad35K++. Overall, our data demonstrate that Ad35K++ and rILYd4 are efficient co-therapeutics of daratumumab and isatuximab, specifically in multi-cycle treatment regimens, and could be used to improve treatment of multiple myeloma.https://www.tandfonline.com/doi/10.1080/15384047.2024.2314322Multiple myelomadaratumumabisatuximabcomplement dependent cytotoxicityresistance |
| spellingShingle | Hongjie Wang Theo Koob Jonathan R. Fromm Ajay Gopal Darrick Carter André Lieber CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells Cancer Biology & Therapy Multiple myeloma daratumumab isatuximab complement dependent cytotoxicity resistance |
| title | CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells |
| title_full | CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells |
| title_fullStr | CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells |
| title_full_unstemmed | CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells |
| title_short | CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells |
| title_sort | cd46 and cd59 inhibitors enhance complement dependent cytotoxicity of anti cd38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other b cell malignancy cells |
| topic | Multiple myeloma daratumumab isatuximab complement dependent cytotoxicity resistance |
| url | https://www.tandfonline.com/doi/10.1080/15384047.2024.2314322 |
| work_keys_str_mv | AT hongjiewang cd46andcd59inhibitorsenhancecomplementdependentcytotoxicityofanticd38monoclonalantibodiesdaratumumabandisatuximabinmultiplemyelomaandotherbcellmalignancycells AT theokoob cd46andcd59inhibitorsenhancecomplementdependentcytotoxicityofanticd38monoclonalantibodiesdaratumumabandisatuximabinmultiplemyelomaandotherbcellmalignancycells AT jonathanrfromm cd46andcd59inhibitorsenhancecomplementdependentcytotoxicityofanticd38monoclonalantibodiesdaratumumabandisatuximabinmultiplemyelomaandotherbcellmalignancycells AT ajaygopal cd46andcd59inhibitorsenhancecomplementdependentcytotoxicityofanticd38monoclonalantibodiesdaratumumabandisatuximabinmultiplemyelomaandotherbcellmalignancycells AT darrickcarter cd46andcd59inhibitorsenhancecomplementdependentcytotoxicityofanticd38monoclonalantibodiesdaratumumabandisatuximabinmultiplemyelomaandotherbcellmalignancycells AT andrelieber cd46andcd59inhibitorsenhancecomplementdependentcytotoxicityofanticd38monoclonalantibodiesdaratumumabandisatuximabinmultiplemyelomaandotherbcellmalignancycells |